Company

SPHEBIO

SPHEBIO develops biomimetic materials and 3D cell culture technology for biomedical applications.

About

SPHEBIO develops biomimetic materials and 3D cell culture technology for tissue modeling, regenerative medicine, and pharmaceutical research. It serves research institutions, pharmaceutical companies, and healthcare providers. Founded in 2020, the company is based in Pohang, South Korea. In August 2023, it raised KRW 4.5 billion in Series A funding from Korea Investment & Securities, Company K Partners, and Paratus Investment.

2Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in